Matches in Wikidata for { <http://www.wikidata.org/entity/Q93034623> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q93034623 description "article scientifique publié en 2020" @default.
- Q93034623 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q93034623 description "scientific article published on 30 January 2020" @default.
- Q93034623 description "wetenschappelijk artikel" @default.
- Q93034623 description "наукова стаття, опублікована 30 січня 2020" @default.
- Q93034623 name "How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials" @default.
- Q93034623 name "How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials" @default.
- Q93034623 type Item @default.
- Q93034623 label "How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials" @default.
- Q93034623 label "How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials" @default.
- Q93034623 prefLabel "How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials" @default.
- Q93034623 prefLabel "How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials" @default.
- Q93034623 P1433 Q93034623-DB972C2B-2604-4675-905A-F445CB9D2C38 @default.
- Q93034623 P1476 Q93034623-1F588738-54AF-4D2C-8DD1-9C4435F596DD @default.
- Q93034623 P2093 Q93034623-644ACBB8-30B4-4766-B834-516E7BC7D847 @default.
- Q93034623 P2093 Q93034623-738C26F6-087E-442D-8952-5C95A4134DA7 @default.
- Q93034623 P304 Q93034623-14BEFF00-8E03-4745-A1D6-F9FA6340546F @default.
- Q93034623 P31 Q93034623-920AA27B-D0AC-40D6-8C47-15BA964D5E69 @default.
- Q93034623 P356 Q93034623-8330205F-59B2-4876-904C-4DE899A6DB1C @default.
- Q93034623 P433 Q93034623-6E8E105F-114F-4ACF-BCA0-F1374C8C5D59 @default.
- Q93034623 P478 Q93034623-C625BCFB-9B68-45D1-944E-EBFE70A17881 @default.
- Q93034623 P50 Q93034623-7969650B-F66F-445E-81D4-F9212134CD1D @default.
- Q93034623 P50 Q93034623-A6C95274-9182-4530-9777-5321316BB634 @default.
- Q93034623 P577 Q93034623-70F4ABB6-6782-4F32-B577-47F5B1E04A5C @default.
- Q93034623 P698 Q93034623-9F7D1938-FD27-4215-A8CF-2E9F09E0BD01 @default.
- Q93034623 P356 ATVBAHA.119.311904 @default.
- Q93034623 P698 31996025 @default.
- Q93034623 P1433 Q4797542 @default.
- Q93034623 P1476 "How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials" @default.
- Q93034623 P2093 "Mark C Petrie" @default.
- Q93034623 P2093 "Naveed Sattar" @default.
- Q93034623 P304 "506-522" @default.
- Q93034623 P31 Q13442814 @default.
- Q93034623 P356 "10.1161/ATVBAHA.119.311904" @default.
- Q93034623 P433 "3" @default.
- Q93034623 P478 "40" @default.
- Q93034623 P50 Q56633150 @default.
- Q93034623 P50 Q57786218 @default.
- Q93034623 P577 "2020-01-30T00:00:00Z" @default.
- Q93034623 P698 "31996025" @default.